Pet Pharm Biotech Co., Ltd. (7762)
TWSE
58.10
+0.10 (+0.17%)
Closed
Aug 25, 2026
Day's Range
56.1058.20
52 wk Range
44.0089.85
Financial Statements - 7762 - Pet Pharm Biotech Co., Ltd.
Revenue
222.03M▲ 69.9%
Net Income
24.89M▲ 71.6%Net Margin 11.2%
EBITDA
59.66M▲ 85.4%
Free Cash Flow
4.41M▲ 102.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Sales | 222.03M | 130.70M | 117.86M | 75.74M |
| Cost of Goods | 105.58M | 60.73M | 53.27M | 39.88M |
| Gross Profit | 116.44M | 69.96M | 64.59M | 35.85M |
 Operating Expense | - | - | - | - |
| Operating Income | 14.76M | 8.08M | 6.38M | -3.63M |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | - | - | - | - |
| Pre Tax Income | 24.17M | 12.41M | 9.14M | -3.81M |
| Income Tax | -723K | -2.08M | 0 | 0 |
| Net Income | 24.89M | 14.50M | 9.14M | -3.81M |
| EPS Basic | - | 0.36 | 0.300041 | -0.158923 |
| EPS Diluted | - | 0.36 | 0.300041 | -0.158923 |
| Basic Shares Outstanding | - | 40.50M | 30.30M | 24.64M |
| Diluted Shares Outstanding | - | 40.50M | 30.30M | 24.64M |
| Ebit | 25.06M | 12.59M | 9.32M | -3.61M |
| Ebitda | 59.66M | 32.17M | 24.87M | 11.88M |
| Net Income Continuous Operations | 24.17M | 12.41M | 9.14M | -3.81M |
| Minority Interests | 88K | 0 | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
